Skip to content

Peter Blume-Jensen, President and CEO at Acrivon Therapeutics, sold ACRV on Aug 25, 2026

Data as of Oct 16

▼ SELL$31K14,036 shares at $2.21Peter Blume-Jensen President and CEOACRV Acrivon Therapeutics, Inc.
Watch ACRV
Traded
Aug 25, 2026
Disclosed
Aug 27, 2026
Filed
2 days after the trade

Form 4s are due within two business days.

Official filing (SEC Form 4) ↗

The price around the disclosure

Peter Blume-Jensen, President and CEO at Acrivon Therapeutics, sold ACRV on Aug 25, 2026TRADEDDISCLOSED
ACRVSimilar stocks (XLV — its sector index fund), rebased to ACRV's price on the disclosure day
ACRV since disclosure
−23.7%
after the sale
Similar stocks (XLV) since disclosure
+3.0%
XLV — its sector index fund

Change in closing price from Aug 27, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.

Our take

None of our tested rules fired on this trade.

Other trades in the same filing

  1. ▼ SELLKristina Masson EVP - Business OperationsACRV Acrivon Therapeutics, Inc.$31Kdisclosed Aug 27 · filed 2 days after the trade

See every trade on ACRV →